Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction

Fig. 2

Correlation between RIPK2 expression and overall survival and disease-free survival of patients in different kinds of tumor. A Survival map (OS) from the online tool GEPIA2 (upper panel). Kaplan–Meier survival plots (OS) comparing high and low expression of RIPK2 in different kinds of cancer (CESC, KIRP, LIHC, LUAD, PAAD, THYM, UVM) (lower panel). B Survival map (DFS) from the online tool GEPIA (upper panel). Kaplan–Meier survival plots (DFS) comparing high and low expression of RIPK2 in different kinds of cancer (KICH, KIRC, KIRP, LUSC, SARC, UVM) (lower panel)

Back to article page

Molecular Medicine

ISSN: 1528-3658